NCT00645502View on ClinicalTrials.gov

Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

July 31, 2003

Conditions
SchizophreniaSchizoaffective Disorders
Interventions
DRUG

risperidone

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00645502 - Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet. | Biotech Hunter | Biotech Hunter